Free Trial

Insulet (PODD) Stock Forecast & Price Target

Insulet logo
$260.72 -2.63 (-1.00%)
(As of 09:46 AM ET)

Insulet - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
13

Based on 16 Wall Street analysts who have issued ratings for Insulet in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for PODD.

Consensus Price Target

$267.44
2.58% Upside
According to the 16 analysts' twelve-month price targets for Insulet, the average price target is $267.44. The highest price target for PODD is $330.00, while the lowest price target for PODD is $200.00. The average price target represents a forecasted upside of 2.58% from the current price of $260.72.
Get the Latest News and Ratings for PODD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Insulet and its competitors.

Sign Up

PODD Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$267.44$253.27$229.21$258.07
Forecasted Upside2.58% Upside-2.84% Downside-3.56% Downside20.25% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

PODD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PODD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Insulet Stock vs. The Competition

TypeInsuletMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.58% Upside27,804.18% Upside11.94% Upside
News Sentiment Rating
Positive News

See Recent PODD News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/12/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$280.00 ➝ $330.00+19.70%
12/11/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$283.00 ➝ $310.00+13.12%
12/11/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$290.00 ➝ $305.00+10.20%
12/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$269.00 ➝ $304.00+14.52%
11/11/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$220.00 ➝ $234.00-15.16%
11/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$234.00 ➝ $317.00+18.28%
How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now
11/8/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$260.00 ➝ $270.00-1.61%
11/6/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$300.00+24.32%
10/14/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$213.00 ➝ $260.00+12.57%
9/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$230.00 ➝ $285.00+21.85%
8/9/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$211.00 ➝ $223.00+22.14%
6/10/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
5/30/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$235.00+36.43%
5/10/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $260.00+46.48%
5/7/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$200.00+13.38%
2/5/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$163.00 ➝ $208.00+7.39%
12/21/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$180.00 ➝ $238.00+14.44%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
10/16/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$184.00+35.83%
8/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$365.00 ➝ $295.00+56.48%
8/9/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$350.00 ➝ $300.00+30.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:15 AM ET.


PODD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Insulet is $267.44, with a high forecast of $330.00 and a low forecast of $200.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.

According to analysts, Insulet's stock has a predicted upside of 2.58% based on their 12-month stock forecasts.

Analysts like Insulet more than other "medical" companies. The consensus rating score for Insulet is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how PODD compares to other companies.


This page (NASDAQ:PODD) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners